Applying Standard Guidelines to Practice (Course LC01.02)
Published on April 30, 2007 Audio Interview
Published on April 30, 2007 Audio Interview
Click here to view our current activities in Oncology.
Optimal treatment of lung cancer requires clinicians to remain informed regarding standard treatment guidelines as they evolve. Learn about the latest data and guideline-based approaches to treating both small-cell and non-small-cell lung cancer in this interview with Corey J. Langer, MD, FACP. Listen online or download MP3 audio file. Supplemental slides are also available for download.
Roy S. Herbst, MD, PhD
- Professor of Medicine
- Chief, Section of Thoracic Medical Oncology
- Department of Thoracic/Head and Neck Medical Oncology
- The University of Texas M.D. Anderson Cancer Center
- Houston, Texas
Corey J. Langer, MD, FACP
- Professor of Medicine
- Hematology-Oncology Division
- Department of Medicine
- University of Pennsylvania
- Philadelphia, Pennsylvania
Corey J. Langer, MD, FACP, has received grant/research support from Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc, ImClone Systems, GlaxoSmithKline, OSI Pharmaceuticals, Inc, and Pfizer, Inc; is an advisor for Abbott, Abraxis, Amgen Inc, Ariad Pharmaceuticals, AstraZeneca, Bayer/Onyx, Biodesix, Boerhinger Ingelheim, Bristol-Myers Squibb, Caris Dx, Clarient Inc, Eli Lilly and Company, Genentech Inc, ImClone Systems, Morphotek, Novartis Pharmaceuticals Corporation, Pfizer, Inc, sanofi-aventis, and Synta Pharmaceuticals; and is on the speakers bureau of Genentech, Inc, ImClone-BMS, Eli Lilly and Company, and OSI Pharmaceuticals Inc.
Hak Choy, MD, has received grant/research support from Bristol-Myers Squibb, Imclone Systems Inc, and Eli Lilly and Company; is a consultant for Genentech, Inc; and is a member of the advisory board of Bristol-Myers Squibb, Genentech, Inc, Imclone Systems Inc, and Sanofi-Aventis.
Roy S. Herbst, MD, PhD, has received grant/research support from Amgen Inc, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc, and Taiho Pharmaceutical; is a consultant for Amgen Inc, AstraZeneca, Eli Lilly and Company, and Genentech, Inc; and is on the speakers bureau of AstraZeneca, Eli Lilly and Company, and Genentech, Inc.
Corey J. Langer, MD, FACP, has received grant/research support from Bristol-Myers Squibb, Genentech, Inc, ImClone Systems, Lilly USA, LLC, OSI Pharmaceuticals, Inc. and Pfizer, Inc; is an advisor for Abraxis, Abbott, Amgen, AstraZeneca, Bayer/Onyx, Biodesix, Bristol-Myers Squibb, Caris Dx, Clarient Inc, Genentech Inc, ImClone Systems, Lilly USA, LLC, Morphotek, Novartis Pharmaceuticals, Pfizer, Inc, sanofi-aventis, and is on the speakers bureau of Genentech, Inc, ImClone-BMS, Lilly USA, LLC, and OSI Pharmaceuticals Inc.
Harvey I. Pass, MD, is on the speakers bureau of Eli Lilly and Company and Sanofi-Aventis; and is a member of the advisory board of Sanofi-Aventis.
Alan B. Sandler, MD, has received grant/research support from Amgen Inc, AstraZeneca, Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc, OSI Pharmaceuticals, Inc, Pfizer Inc, and Sanofi-Aventis; is on the speakers bureau of Genentech, Inc; and is a member of the advisory board of Amgen Inc, AstraZeneca, Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, Cyclacel Pharmaceuticals Inc, Eli Lilly and Company, Genentech, Inc, OSI Pharmaceuticals, Inc, Pfizer Inc, Sanofi-Aventis, and Wyeth Pharmaceuticals.
Available for CME/CE:
Physicians
Publish Date: Apr 30, 2007 Termination Date: Apr 30, 2008Nurses
Publish Date: Apr 30, 2007 Termination Date: Apr 30, 2008Pharmacists
Publish Date: Apr 30, 2007 Termination Date: Apr 30, 2008Estimated time for completion of this activity:
CNE: 1.0 hour
CPE: 3.50 hours (30.00 minutes for each audio interview; pharmacists must complete all 7 audio interviews to receive 0.35 CEUs)
Target Audience
This activity is designed for oncologists and other clinicians who specialize in and care for patients with lung cancer.
Activity Goal
The goal of this CME/CE activity is to examine current and emerging strategies for treating and managing patients with lung cancer.
Learning Objective (s)
- Develop appropriate management strategies based on extent of disease for patients with small-cell lung cancer, in accordance with standard guidelines and practice.
- Develop appropriate management strategies based on the TNM disease stage for patients with non-small cell lung cancer, in accordance with standard guidelines and practice.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
This program has been approved by the American Association of Critical-Care Nurses (AACN) for 1.00 contact hour(s). Provider #00013784.
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This audio interview is worth up to 0.5 contact hour (0.05 CEU). The ACPE Universal Program Number assigned to this activity is 052-000-07-002-H01.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Roy S. Herbst, MD, PhD has received grant/research support from Amgen Inc, AstraZeneca, Bristol-Myers Squibb, Genentech, Inc, Geron Corporation, Novartis Pharmaceuticals, Oncothyreon, OSI Pharmaceuticals, Inc. and sanofi-aventis; is an advisor for Amgen Inc, AstraZeneca, Bristol-Myers Squibb, and Eli Lilly and Company; and is a consultant for Amgen Inc, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc, and SynDevRx.
Corey J. Langer, MD, FACP has received grant/research support from Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc, ImClone Systems, GlaxoSmithKline, OSI Pharmaceuticals, Inc, and Pfizer, Inc; is an advisor for Abbott, Abraxis, Amgen Inc, Ariad Pharmaceuticals, AstraZeneca, Bayer/Onyx, Biodesix, Boerhinger Ingelheim, Bristol-Myers Squibb, Caris Dx, Clarient Inc, Eli Lilly and Company, Genentech Inc, ImClone Systems, Morphotek, Novartis Pharmaceuticals Corporation, Pfizer, Inc, sanofi-aventis, and Synta Pharmaceuticals; and is on the speakers bureau of Genentech, Inc, ImClone-BMS, Eli Lilly and Company, and OSI Pharmaceuticals Inc.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Julie R. Brahmer, MD has received grant/research support from AstraZeneca, Medarex Inc, Pfizer Inc, and Wyeth Pharmaceuticals; and is a consultant for and a member of the advisory board of Eli Lilly and Company.
Hak Choy, MD has received grant/research support from Bristol-Myers Squibb, Imclone Systems Inc, and Eli Lilly and Company; is a consultant for Genentech, Inc; and is a member of the advisory board of Bristol-Myers Squibb, Genentech, Inc, Imclone Systems Inc, and Sanofi-Aventis.
Roy S. Herbst, MD, PhD has received grant/research support from Amgen Inc, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc, and Taiho Pharmaceutical; is a consultant for Amgen Inc, AstraZeneca, Eli Lilly and Company, and Genentech, Inc; and is on the speakers bureau of AstraZeneca, Eli Lilly and Company, and Genentech, Inc.
Corey J. Langer, MD, FACP has received grant/research support from Bristol-Myers Squibb, Genentech, Inc, ImClone Systems, Lilly USA, LLC, OSI Pharmaceuticals, Inc. and Pfizer, Inc; is an advisor for Abraxis, Abbott, Amgen, AstraZeneca, Bayer/Onyx, Biodesix, Bristol-Myers Squibb, Caris Dx, Clarient Inc, Genentech Inc, ImClone Systems, Lilly USA, LLC, Morphotek, Novartis Pharmaceuticals, Pfizer, Inc, sanofi-aventis, and is on the speakers bureau of Genentech, Inc, ImClone-BMS, Lilly USA, LLC, and OSI Pharmaceuticals Inc.
Harvey I. Pass, MD is on the speakers bureau of Eli Lilly and Company and Sanofi-Aventis; and is a member of the advisory board of Sanofi-Aventis.
Alan B. Sandler, MD has received grant/research support from Amgen Inc, AstraZeneca, Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc, OSI Pharmaceuticals, Inc, Pfizer Inc, and Sanofi-Aventis; is on the speakers bureau of Genentech, Inc; and is a member of the advisory board of Amgen Inc, AstraZeneca, Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, Cyclacel Pharmaceuticals Inc, Eli Lilly and Company, Genentech, Inc, OSI Pharmaceuticals, Inc, Pfizer Inc, Sanofi-Aventis, and Wyeth Pharmaceuticals.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
OSI Oncology
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Available for CME/CE:
Physicians
Publish Date: Apr 30, 2007 Termination Date: Apr 30, 2008Nurses
Publish Date: Apr 30, 2007 Termination Date: Apr 30, 2008Pharmacists
Publish Date: Apr 30, 2007 Termination Date: Apr 30, 2008Estimated time for completion of this activity:
CNE: 1.0 hour
CPE: 3.50 hours (30.00 minutes for each audio interview; pharmacists must complete all 7 audio interviews to receive 0.35 CEUs)
Target Audience
This activity is designed for oncologists and other clinicians who specialize in and care for patients with lung cancer.
Activity Goal
The goal of this CME/CE activity is to examine current and emerging strategies for treating and managing patients with lung cancer.
Learning Objective (s)
- Develop appropriate management strategies based on extent of disease for patients with small-cell lung cancer, in accordance with standard guidelines and practice.
- Develop appropriate management strategies based on the TNM disease stage for patients with non-small cell lung cancer, in accordance with standard guidelines and practice.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
This program has been approved by the American Association of Critical-Care Nurses (AACN) for 1.00 contact hour(s). Provider #00013784.
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This audio interview is worth up to 0.5 contact hour (0.05 CEU). The ACPE Universal Program Number assigned to this activity is 052-000-07-002-H01.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Roy S. Herbst, MD, PhD has received grant/research support from Amgen Inc, AstraZeneca, Bristol-Myers Squibb, Genentech, Inc, Geron Corporation, Novartis Pharmaceuticals, Oncothyreon, OSI Pharmaceuticals, Inc. and sanofi-aventis; is an advisor for Amgen Inc, AstraZeneca, Bristol-Myers Squibb, and Eli Lilly and Company; and is a consultant for Amgen Inc, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc, and SynDevRx.
Corey J. Langer, MD, FACP has received grant/research support from Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc, ImClone Systems, GlaxoSmithKline, OSI Pharmaceuticals, Inc, and Pfizer, Inc; is an advisor for Abbott, Abraxis, Amgen Inc, Ariad Pharmaceuticals, AstraZeneca, Bayer/Onyx, Biodesix, Boerhinger Ingelheim, Bristol-Myers Squibb, Caris Dx, Clarient Inc, Eli Lilly and Company, Genentech Inc, ImClone Systems, Morphotek, Novartis Pharmaceuticals Corporation, Pfizer, Inc, sanofi-aventis, and Synta Pharmaceuticals; and is on the speakers bureau of Genentech, Inc, ImClone-BMS, Eli Lilly and Company, and OSI Pharmaceuticals Inc.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Julie R. Brahmer, MD has received grant/research support from AstraZeneca, Medarex Inc, Pfizer Inc, and Wyeth Pharmaceuticals; and is a consultant for and a member of the advisory board of Eli Lilly and Company.
Hak Choy, MD has received grant/research support from Bristol-Myers Squibb, Imclone Systems Inc, and Eli Lilly and Company; is a consultant for Genentech, Inc; and is a member of the advisory board of Bristol-Myers Squibb, Genentech, Inc, Imclone Systems Inc, and Sanofi-Aventis.
Roy S. Herbst, MD, PhD has received grant/research support from Amgen Inc, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc, and Taiho Pharmaceutical; is a consultant for Amgen Inc, AstraZeneca, Eli Lilly and Company, and Genentech, Inc; and is on the speakers bureau of AstraZeneca, Eli Lilly and Company, and Genentech, Inc.
Corey J. Langer, MD, FACP has received grant/research support from Bristol-Myers Squibb, Genentech, Inc, ImClone Systems, Lilly USA, LLC, OSI Pharmaceuticals, Inc. and Pfizer, Inc; is an advisor for Abraxis, Abbott, Amgen, AstraZeneca, Bayer/Onyx, Biodesix, Bristol-Myers Squibb, Caris Dx, Clarient Inc, Genentech Inc, ImClone Systems, Lilly USA, LLC, Morphotek, Novartis Pharmaceuticals, Pfizer, Inc, sanofi-aventis, and is on the speakers bureau of Genentech, Inc, ImClone-BMS, Lilly USA, LLC, and OSI Pharmaceuticals Inc.
Harvey I. Pass, MD is on the speakers bureau of Eli Lilly and Company and Sanofi-Aventis; and is a member of the advisory board of Sanofi-Aventis.
Alan B. Sandler, MD has received grant/research support from Amgen Inc, AstraZeneca, Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc, OSI Pharmaceuticals, Inc, Pfizer Inc, and Sanofi-Aventis; is on the speakers bureau of Genentech, Inc; and is a member of the advisory board of Amgen Inc, AstraZeneca, Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, Cyclacel Pharmaceuticals Inc, Eli Lilly and Company, Genentech, Inc, OSI Pharmaceuticals, Inc, Pfizer Inc, Sanofi-Aventis, and Wyeth Pharmaceuticals.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
OSI Oncology
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
|



